OCX - Oncocyte Corporation
0 0%
Share volume: 0
Last Updated:
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.08%
PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
Summary score
37%
Profitability
35%
Dept financing
43%
Liquidity
70%
Performance
30%
Sector
Manufacturing
Industry
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Long-term ratios 2021 - 2025
The data are presented for the financials results of the quarters of the last 4 years.
Return on equity
0%
Return on assets
-11%
Return on sales
-318.01%
Return on invested capital
0%
Total debt ratio
83.07%
Debt ratio change over timeo
0%
Current Ratio
3.75%
Quick Ratio
3.7%
Cash Position Ratio
3.2%
Short-term ratios 2024 - 2025
The data are presented for the financials results of the quarters of the last year.
Return on equity
0%
Return on assets
-11%
Return on sales
-318.01%
Return on invested capital
0%
Total debt ratio
83.07%
Debt ratio change over timeo
0%
Current Ratio
3.75%
Quick Ratio
3.7%
Cash Position Ratio
3.2%
Last quarter ratios 2025
The data are presented for the financials results of the last quarter.
Return on equity
0%
Return on assets
-11%
Return on sales
-318.01%
Return on invested capital
0%
Total debt ratio
83.07%
Debt ratio change over time
0%
Current Ratio
3.75%
Quick Ratio
3.7%
Cash Position Ratio
3.2%
Performance ratios (change over 4 years) 2021 - 2025
The data are presented for the change financials results of the quarter of the last 4 years.
Return on equity
0%
Return on assets
0%
Return on sales
0%
Return on invested capital
0%
Total debt ratio
0%
Debt ratio change over time
0%
Current Ratio
0%
Quick Ratio
0%
Cash Position Ratio
0%
Compare in sector
The following table compares the individual analyzes for the other top 3 stocks within the same industry.
| Long-term ratios | OCX | IDXX | LNTH | QDEL |
|---|---|---|---|---|
| Return on equity | 0% | 25.94% | 2.75% | 12.38% |
| Return on assets | -11% | 8.91% | 3.36% | 12.68% |
| Return on sales | -318.01% | 28.65% | 13.46% | 47.92% |
| Return on invested capital | 0% | 31.07% | 6.84% | 44.44% |
| Profitability | 0% | 75% | 20% | 87% |
| Total debt ratio | 83.07% | 64.76% | 48.84% | 21.73% |
| Debt ratio change over time | 0% | 1.34% | -5.52% | 1.42% |
| Dept financing | 25% | 43% | 15% | 32% |
| Current Ratio | 3.75% | 1.32% | 4.4% | 0% |
| Quick Ratio | 3.7% | 0.96% | 4.17% | 0% |
| Cash Position Ratio | 3.2% | 0.27% | 2.89% | 0% |
| Liquididy | 72% | 15% | 60% | 69% |
| Short-term ratios | OCX | IDXX | LNTH | QDEL |
|---|---|---|---|---|
| Return on equity | 0% | 0% | 0% | 0% |
| Return on assets | -11% | 8.65% | 6.16% | 0% |
| Return on sales | -318.01% | 29.14% | 29.47% | 0% |
| Return on invested capital | 0% | 0% | 0% | 0% |
| Profitability | 50% | 50% | 43% | 0% |
| Total debt ratio | 83.07% | 52.98% | 44.48% | 0% |
| Debt ratio change over time | 0% | 0% | 0% | 0% |
| Dept financing | 50% | 16% | 13% | 0% |
| Current Ratio | 3.75% | 1.32% | 4.4% | 0% |
| Quick Ratio | 3.7% | 0.96% | 4.17% | 0% |
| Cash Position Ratio | 3.2% | 0.27% | 2.89% | 0% |
| Liquididy | 68% | 15% | 73% | 0% |